{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:01:08Z","timestamp":1776394868995,"version":"3.51.2"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04952-9","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:12:02Z","timestamp":1768205522000},"page":"9245-9257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological and speech-language pathology management of dysphagia in patients with myasthenia gravis"],"prefix":"10.1007","volume":"399","author":[{"given":"F.","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"De Berardinis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"4952_CR1","doi-asserted-by":"publisher","unstructured":"Amitrano A (2024) Treatment of dysphagia in adult dysphagic patients. In: Dysphagia and Nutrition. Springer, Cham. https:\/\/doi.org\/10.1007\/978-3-031-77449-2_4","DOI":"10.1007\/978-3-031-77449-2_4"},{"issue":"6","key":"4952_CR2","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1007\/s00415-021-10902-1","volume":"269","author":"LK Andersen","year":"2022","unstructured":"Andersen LK, Jakobsson AS, Revsbech KL, Vissing J (2022) Causes of symptom dissatisfaction in patients with generalized myasthenia gravis. J Neurol 269(6):3086\u20133093. https:\/\/doi.org\/10.1007\/s00415-021-10902-1","journal-title":"J Neurol"},{"issue":"1","key":"4952_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1573-2","volume":"19","author":"ED Bacci","year":"2019","unstructured":"Bacci ED, Coyne KS, Poon JL, Harris L, Boscoe AN (2019) Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol 19(1):335. https:\/\/doi.org\/10.1186\/s12883-019-1573-2","journal-title":"BMC Neurol"},{"issue":"6","key":"4952_CR4","doi-asserted-by":"publisher","first-page":"900","DOI":"10.23736\/S1973-9087.21.06716-2","volume":"57","author":"AV Bai","year":"2021","unstructured":"Bai AV, Agostini F, Bernetti A, Mangone M, Fidenzi G, D\u2019Urzo R, Ruggiero M, Murgia M, Santilli V, Paoloni M, Ruoppolo G, Masiero S (2021) State of the evidence about rehabilitation interventions in patients with dysphagia. Eur J Phys Rehabil Med 57(6):900\u2013911. https:\/\/doi.org\/10.23736\/S1973-9087.21.06716-2","journal-title":"Eur J Phys Rehabil Med"},{"issue":"6 Pt A","key":"4952_CR5","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.clnu.2017.09.002","volume":"37","author":"AM Beck","year":"2018","unstructured":"Beck AM, Kjaersgaard A, Hansen T, Poulsen I (2018) Systematic review and evidence based recommendations on texture modified foods and thickened liquids for adults (above 17 years) with oropharyngeal dysphagia - an updated clinical guideline. Clin Nutr 37(6 Pt A):1980\u20131991. https:\/\/doi.org\/10.1016\/j.clnu.2017.09.002","journal-title":"Clin Nutr"},{"issue":"3","key":"4952_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.24769","volume":"53","author":"M Benatar","year":"2016","unstructured":"Benatar M, Mcdermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ, Hehir M, Juel V, Katzberg H, Tawil R, Muscle study group (MSG) (2016) Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve 53(3):363\u2013369. https:\/\/doi.org\/10.1002\/mus.24769","journal-title":"Muscle Nerve"},{"issue":"11","key":"4952_CR7","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s40265-024-02101-9","volume":"84","author":"HA Blair","year":"2024","unstructured":"Blair HA (2024) Efgartigimod: a review in generalised myasthenia gravis. Drugs 84(11):1463\u20131474. https:\/\/doi.org\/10.1007\/s40265-024-02101-9","journal-title":"Drugs"},{"issue":"5","key":"4952_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22(5):383\u2013394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"issue":"3","key":"4952_CR9","first-page":"165","volume":"32","author":"MB Brodsky","year":"2024","unstructured":"Brodsky MB, Miles A (2024) Dysphagia rehabilitation: is it time to challenge the dogma in neuromuscular disease? Curr Opin Otolaryngol Head Neck Surg 32(3):165\u2013172","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"3","key":"4952_CR10","first-page":"165","volume":"32","author":"MB Brodsky","year":"2024","unstructured":"Brodsky MB, Miles A (2024) Dysphagia rehabilitation: is it time to challenge the dogma in neuromuscular disease? Curr Opin Otolaryngol Head Neck Surg 32(3):165\u2013172","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"12","key":"4952_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","volume":"12","author":"PM Brown","year":"2016","unstructured":"Brown PM, Pratt AG, Isaacs JD (2016) Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 12(12):731\u2013742. https:\/\/doi.org\/10.1038\/nrrheum.2016.175","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"4952_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"AM Bubuioc","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA (2021) The epidemiology of myasthenia gravis. J Med Life 14(1):7\u201316. https:\/\/doi.org\/10.25122\/jml-2020-0145","journal-title":"J Med Life"},{"issue":"1","key":"4952_CR13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.clnu.2017.09.003","volume":"37","author":"R Burgos","year":"2018","unstructured":"Burgos R, Bret\u00f3n I, Cereda E, Desport JC, Dziewas R, Genton L, Gomes F, J\u00e9sus P, Leischker A, Muscaritoli M, Poulia KA, Preiser JC, Van der Marck M, Wirth R, Singer P, Bischoff SC (2018) Espen guideline clinical nutrition in neurology. Clin Nutr 37(1):354\u2013396. https:\/\/doi.org\/10.1016\/j.clnu.2017.09.003","journal-title":"Clin Nutr"},{"key":"4952_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1404191","volume":"15","author":"P Cavalcante","year":"2024","unstructured":"Cavalcante P, Mantegazza R, Antozzi C (2024) Targeting autoimmune mechanisms by precision medicine in myasthenia gravis. Front Immunol 15:1404191. https:\/\/doi.org\/10.3389\/fimmu.2024.1404191","journal-title":"Front Immunol"},{"key":"4952_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1280226","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen H, Qiu Y, Yin Z, Wang Z, Tang Y, Ni H, Lu J, Chen Z, Kong Y, Wang Z (2023) Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis. Front Immunol 14:1280226. https:\/\/doi.org\/10.3389\/fimmu.2023.1280226","journal-title":"Front Immunol"},{"issue":"8","key":"4952_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/wnl.55.3.448","volume":"55","author":"E Ciafaloni","year":"2000","unstructured":"Ciafaloni E, Nikhar NK, Massey JM, Sanders DB (2000) Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 55(8):448\u2013450. https:\/\/doi.org\/10.1212\/wnl.55.3.448","journal-title":"Neurology"},{"issue":"9","key":"4952_CR17","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","volume":"73","author":"E Cort\u00e9s-Vicente","year":"2016","unstructured":"Cort\u00e9s-Vicente E, Gallardo E, Mart\u00ednez M\u00c1, D\u00edaz-Manera J, Querol L, Rojas-Garc\u00eda R, Illa I (2016) Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin. JAMA Neurol 73(9):1099\u20131104. https:\/\/doi.org\/10.1001\/jamaneurol.2016.2032","journal-title":"JAMA Neurol"},{"issue":"10","key":"4952_CR18","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s12325-023-02604-z","volume":"40","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Phillips G, Paci S, De Ruyck F, Tollenaar NH, Janssen MF (2023a) People diagnosed with myasthenia gravis have lower health-related quality of life and need more medical and caregiver help in comparison to the general population: analysis of two observational studies. Adv Ther 40(10):4377\u20134394. https:\/\/doi.org\/10.1007\/s12325-023-02604-z","journal-title":"Adv Ther"},{"key":"4952_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066445","volume":"13","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Philips G, Paci S, Beauchamp J, Chiroli S, Quinn C, Day L, Larkin M, Palace J, Berrih-Aknin S, Claeys KG, Muppidi S, Mantegazza R, Sacc\u00e0 F, Meisel A, Bassez G, Murai H, Janssen MF (2023b) Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open 13:e066445. https:\/\/doi.org\/10.1136\/bmjopen-2022-066445","journal-title":"BMJ Open"},{"issue":"4","key":"4952_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.36185\/2532-1900-038","volume":"39","author":"F Deymeer","year":"2020","unstructured":"Deymeer F (2020) Myasthenia gravis: MuSK MG, late-onset MG and ocular MG. Acta Myol 39(4):345\u2013352. https:\/\/doi.org\/10.36185\/2532-1900-038","journal-title":"Acta Myol"},{"issue":"11","key":"4952_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B (2021) Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med 10(11):2235. https:\/\/doi.org\/10.3390\/jcm10112235","journal-title":"J Clin Med"},{"key":"4952_CR22","unstructured":"Duan Z, Zhao J, Zhang Y et al (2023) Effects of respiratory muscle training on pulmonary function and functional capacity in patients with myasthenia gravis: a systematic review and meta-analysis. Front Neurol 14:1128362. Published 2023 Feb 16"},{"issue":"5","key":"4952_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14737175.2023.2207739","volume":"23","author":"A Evoli","year":"2023","unstructured":"Evoli A, Damato V (2023) Conventional and emerging treatments and controversies in myasthenia gravis. Expert Rev Neurother 23(5):445\u2013456. https:\/\/doi.org\/10.1080\/14737175.2023.2207739","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"4952_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ (2018) Treatment of myasthenia gravis. Neurol Clin 36(2):311\u2013337. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.011","journal-title":"Neurol Clin"},{"issue":"2","key":"4952_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Barohn RJ (2018) Treatment of myasthenia gravis: an update. Neurol Clin 36(2):311\u2013337","journal-title":"Neurol Clin"},{"issue":"11","key":"4952_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00776","volume":"27","author":"ML Fichtner","year":"2020","unstructured":"Fichtner ML, Jiang R, Bourke A, Nowak RJ, O\u2019Connor KC (2020) Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol 27(11):776. https:\/\/doi.org\/10.3389\/fimmu.2020.00776","journal-title":"Front Immunol"},{"issue":"1","key":"4952_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/oto2.70077","volume":"9","author":"TJ Gallagher","year":"2025","unstructured":"Gallagher TJ, Maria CS, Johns MM (2025) Prevalence of speech and swallowing dysfunction and intervention among individuals with myasthenia gravis. OTO Open 9(1):e70077. https:\/\/doi.org\/10.1002\/oto2.70077","journal-title":"OTO Open"},{"key":"4952_CR28","doi-asserted-by":"publisher","unstructured":"Garamendi-Ruiz I, G\u00f3mez-Esteban JC (2019) Cardiovascular autonomic effects of vagus nerve stimulation. Clin Auton Res 29(2):183\u2013194. https:\/\/doi.org\/10.1007\/s10286-017-0477-8","DOI":"10.1007\/s10286-017-0477-8"},{"key":"4952_CR29","unstructured":"Garamendi-Ruiz I, G\u00f3mez-Andr\u00e9s D (2022) Neuromuscular diseases and dysphagia: a path to precision medicine. Nutr Hosp 39(Spec No2):28\u201333. (Focus on specific assessment needs in NMDs)"},{"issue":"3","key":"4952_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.medcli.2023.04.006","volume":"161","author":"DA Garc\u00eda Est\u00e9vez","year":"2023","unstructured":"Garc\u00eda Est\u00e9vez DA, Pardo Fern\u00e1ndez J (2023) Myasthenia gravis. Update on diagnosis and therapy. Med Clin (Barc) 161(3):119\u2013127. https:\/\/doi.org\/10.1016\/j.medcli.2023.04.006","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"4952_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S (2016) Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12(5):259\u2013268. https:\/\/doi.org\/10.1038\/nrneurol.2016.44","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"4952_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM (2019) Myasthenia Gravis. Nat Rev Dis Primers 5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"4952_CR33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000506310","volume":"54","author":"E Guastafierro","year":"2020","unstructured":"Guastafierro E, Tramacere I, Toppo C, Leonardi M, Mantegazza R, Bonanno S, Frangiamore R, Raggi A (2020) Employment in myasthenia gravis: a systematic literature review and meta-analysis. Neuroepidemiology 54(4):304\u2013312. https:\/\/doi.org\/10.1159\/000506310","journal-title":"Neuroepidemiology"},{"issue":"11","key":"4952_CR34","volume":"21","author":"AC Guidon","year":"2021","unstructured":"Guidon AC (2021) Bulbar myasthenia gravis: challenges in management. Curr Neurol Neurosci Rep 21(11):62","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"4952_CR35","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1212\/CON.0000000000001161","volume":"28","author":"MK Hehir","year":"2022","unstructured":"Hehir MK, Li Y (2022) Diagnosis and management of myasthenia gravis. Continuum Minneap Minn 28(6):1615\u20131642. https:\/\/doi.org\/10.1212\/CON.0000000000001161","journal-title":"Continuum Minneap Minn"},{"key":"4952_CR36","volume":"14","author":"MK Hehir","year":"2023","unstructured":"Hehir MK, Silvestri NJ (2023) Precision medicine in the management of myasthenia gravis: from antibodies to therapy. Front Neurol 14:1164210","journal-title":"Front Neurol"},{"issue":"5","key":"4952_CR37","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/mus.21640","volume":"41","author":"MK Hehir","year":"2010","unstructured":"Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB (2010) Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 41(5):593\u2013598. https:\/\/doi.org\/10.1002\/mus.21640","journal-title":"Muscle Nerve"},{"issue":"10","key":"4952_CR38","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.2169\/internalmedicine.4303-24","volume":"64","author":"K Himuro","year":"2025","unstructured":"Himuro K, Uzawa A, Kawaguchi N, Kanai T, Isono S, Kuwabara S (2025) Quantitative assessment of dysphagia in myasthenia gravis. Intern Med 64(10):1503\u20131509. https:\/\/doi.org\/10.2169\/internalmedicine.4303-24","journal-title":"Intern Med"},{"issue":"12","key":"4952_CR39","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"issue":"5","key":"4952_CR40","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard Jr","year":"2020","unstructured":"Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF Jr, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M (2020) Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol 77(5):582\u2013592. https:\/\/doi.org\/10.1001\/jamaneurol.2019.5125","journal-title":"JAMA Neurol"},{"issue":"7","key":"4952_CR41","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T et al (2021b) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"issue":"7","key":"4952_CR42","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R, ADAPT Investigator Study Group (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"issue":"2","key":"4952_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0022-5223(19)35365-6","volume":"95","author":"MH Huang","year":"1988","unstructured":"Huang MH, King KL, Chien KY (1988) Esophageal manometric studies in patients with myasthenia gravis. J Thorac Cardiovasc Surg 95(2):281\u2013285","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"4952_CR44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio R (2024) Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol 20(2):84\u201398. https:\/\/doi.org\/10.1038\/s41582-023-00916-w","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"4952_CR45","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1038\/s41433-024-03133-x","volume":"38","author":"S Jacob","year":"2024","unstructured":"Jacob S (2024) Treating myasthenia gravis beyond the eye clinic. Eye Lond 38(12):2422\u20132436. https:\/\/doi.org\/10.1038\/s41433-024-03133-x","journal-title":"Eye Lond"},{"key":"4952_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/874680","volume":"2012","author":"A Jayam Trouth","year":"2012","unstructured":"Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J (2012) Myasthenia gravis: a review. Autoimmune Dis 2012:874680. https:\/\/doi.org\/10.1155\/2012\/874680","journal-title":"Autoimmune Dis"},{"issue":"12","key":"4952_CR47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742","volume":"134","author":"HJ Kaminski","year":"2024","unstructured":"Kaminski HJ, Sikorski P, Coronel SI, Kusner LL (2024) Myasthenia gravis: the future is here. J Clin Invest 134(12):e179742. https:\/\/doi.org\/10.1172\/JCI179742","journal-title":"J Clin Invest"},{"issue":"3","key":"4952_CR48","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/s0025-7125(16)30240-1","volume":"77","author":"WM Koch","year":"1993","unstructured":"Koch WM (1993) Swallowing disorders. Diagnosis and therapy. Med Clin North Am 77(3):571\u2013582. https:\/\/doi.org\/10.1016\/s0025-7125(16)30240-1","journal-title":"Med Clin North Am"},{"issue":"4","key":"4952_CR49","first-page":"1021","volume":"38","author":"T Kogason","year":"2023","unstructured":"Kogason T, Poh K, Li C (2023) Point-of-care ultrasound in the assessment of bulbar dysfunction: a narrative review. Dysphagia 38(4):1021\u20131033","journal-title":"Dysphagia"},{"issue":"2","key":"4952_CR50","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","volume":"10","author":"N Law","year":"2021","unstructured":"Law N, Davio K, Blunck M, Lobban D, Seddik K (2021) The lived experience of myasthenia gravis: a patient-led analysis. Neurol Ther 10(2):1103\u20131125. https:\/\/doi.org\/10.1007\/s40120-021-00285-w","journal-title":"Neurol Ther"},{"key":"4952_CR51","unstructured":"Mao Z, Hu X, Yi Q et al (2024) Quality of life in myasthenia gravis patients with dysphagia: a cross-sectional study using the Dysphagia Handicap Index. BMC Neurol 24(1):58. Published 2024 Feb 5"},{"issue":"9","key":"4952_CR52","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1007\/s10072-022-06175-9","volume":"43","author":"L Mariani","year":"2022","unstructured":"Mariani L, Cilfone A, Nicastri M, Pipitone LL, Stella F, de Vincentiis M, Greco A, Mancini P, Longo L, Ruoppolo G (2022) Accuracy of dysphagia standard assessment (DSA\u00ae) bedside screening test: a flowchart for patient eligibility. Neurol Sci 43(9):5411\u20135419. https:\/\/doi.org\/10.1007\/s10072-022-06175-9","journal-title":"Neurol Sci"},{"issue":"5","key":"4952_CR53","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/1750743X.2025.2491295","volume":"17","author":"A Matic","year":"2025","unstructured":"Matic A, Bril V (2025) Rozanolixizumab for myasthenia gravis: a breakthrough treatment and future prospects. Immunotherapy 17(5):309\u2013316. https:\/\/doi.org\/10.1080\/1750743X.2025.2491295","journal-title":"Immunotherapy"},{"issue":"3","key":"4952_CR54","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1172\/JCI113401","volume":"81","author":"A Melms","year":"1988","unstructured":"Melms A, Schalke BC, Kirchner T, M\u00fcller-Hermelink HK, Albert E, Wekerle H (1988) Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J Clin Invest 81(3):902\u2013908. https:\/\/doi.org\/10.1172\/JCI113401","journal-title":"J Clin Invest"},{"issue":"8","key":"4952_CR55","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V (2022) Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs 82(8):865\u2013887. https:\/\/doi.org\/10.1007\/s40265-022-01726-y","journal-title":"Drugs"},{"key":"4952_CR56","volume":"66","author":"Z Msarah","year":"2022","unstructured":"Msarah Z, Alghadir AH (2022) Assessment of fatigue in swallowing muscles in patients with neuromuscular disorders: a scoping review. J Electromyogr Kinesiol 66:102692","journal-title":"J Electromyogr Kinesiol"},{"issue":"3","key":"4952_CR57","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J (2021) International consensus guidance for management of Myasthenia Gravis: 2020 Update. Neurology 96(3):114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"issue":"14","key":"4952_CR58","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1212\/WNL.0000000000012604","volume":"97","author":"M Petersson","year":"2021","unstructured":"Petersson M, Feresiadou A, Jons D, Ilinca A, Lundin F, Johansson R, Budzianowska A, Roos AK, K\u00e5gstr\u00f6m V, Gunnarsson M, Sundstr\u00f6m P, Piehl F, Brauner S (2021) Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG study. Neurology 97(14):e1382\u2013e1391. https:\/\/doi.org\/10.1212\/WNL.0000000000012604","journal-title":"Neurology"},{"key":"4952_CR59","first-page":"578263","volume":"386","author":"Z Ruan","year":"2024","unstructured":"Ruan Z, Li Y, Liu W et al (2024) Efficacy of novel targeted therapies on bulbar symptoms in generalized myasthenia gravis: a network meta-analysis of randomized controlled trials. J Neuroimmunol 386:578263","journal-title":"J Neuroimmunol"},{"issue":"6","key":"4952_CR60","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/mus.28386","volume":"71","author":"E Sabatelli","year":"2025","unstructured":"Sabatelli E, Bonagura L, Falso S, Marini S, Papi C, Campetella L, De Maio MM, Iorio R (2025) Light sensitivity in myasthenia gravis: clinical characteristics and impact on quality of life. Muscle Nerve 71(6):1081\u20131085. https:\/\/doi.org\/10.1002\/mus.28386","journal-title":"Muscle Nerve"},{"key":"4952_CR61","first-page":"175628642312233","volume":"17","author":"F Sacc\u00e0","year":"2024","unstructured":"Sacc\u00e0 F, Pane C, Muccioli L et al (2024a) Efgartigimod for the treatment of generalized myasthenia gravis: real-world evidence and clinical positioning. Ther Adv Neurol Disord 17:17562864231223344","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"4952_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180","volume":"31","author":"F Sacc\u00e0","year":"2024","unstructured":"Sacc\u00e0 F, Salort-Campana E, Jacob S, Cort\u00e9s-Vicente E, Schneider-Gold C (2024b) Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. Eur J Neurol 31(6):e16180. https:\/\/doi.org\/10.1111\/ene.16180","journal-title":"Eur J Neurol"},{"key":"4952_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ensci.2016.02.004","volume":"2","author":"W Sakai","year":"2016","unstructured":"Sakai W, Matsui N, Ishida M, Furukawa T, Miyazaki Y, Fujita K, Miyamoto R, Yamamoto N, Sako W, Sato K, Kondo K, Nishida Y, Mitsui T, Izumi Y, Kaji R (2016) Late-onset myasthenia gravis is predisposed to become generalized in the elderly. eNeurologicalSci 2:17\u201320. https:\/\/doi.org\/10.1016\/j.ensci.2016.02.004","journal-title":"eNeurologicalSci"},{"issue":"21","key":"4952_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216394","volume":"11","author":"D S\u00e1nchez-Tejerina","year":"2022","unstructured":"S\u00e1nchez-Tejerina D, Sotoca J, Llaurado A, L\u00f3pez-Diego V, Juntas-Morales R, Salvado M (2022) New targeted agents in myasthenia gravis and future therapeutic strategies. J Clin Med 11(21):6394. https:\/\/doi.org\/10.3390\/jcm11216394","journal-title":"J Clin Med"},{"issue":"5\u20136","key":"4952_CR65","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","volume":"43","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Evoli A (2010) Immunosuppressive therapies in myasthenia gravis. Autoimmunity 43(5\u20136):428\u2013435. https:\/\/doi.org\/10.3109\/08916930903518107","journal-title":"Autoimmunity"},{"issue":"26","key":"4952_CR66","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87(26):419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"4952_CR67","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T (2019a) Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord 12:1756286419832242. https:\/\/doi.org\/10.1177\/1756286419832242","journal-title":"Ther Adv Neurol Disord"},{"key":"4952_CR68","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T (2019b) Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord 12:1756286419832242. https:\/\/doi.org\/10.1177\/1756286419832242","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"4952_CR69","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/17549507.2021.1961862","volume":"24","author":"K Shrubsole","year":"2022","unstructured":"Shrubsole K, Cavanagh N, Alsop T (2022) Do people with myasthenia gravis need speech-language pathology services? A national survey of consumers\u2019 experiences and perspectives. Int J Speech Lang Pathol 24(2):133\u2013144. https:\/\/doi.org\/10.1080\/17549507.2021.1961862","journal-title":"Int J Speech Lang Pathol"},{"issue":"2","key":"4952_CR70","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/08164622.2022.2029683","volume":"105","author":"NH Shuey","year":"2022","unstructured":"Shuey NH (2022) Ocular myasthenia gravis: a review and practical guide for clinicians. Clin Exp Optom 105(2):205\u2013213. https:\/\/doi.org\/10.1080\/08164622.2022.2029683","journal-title":"Clin Exp Optom"},{"issue":"2","key":"4952_CR71","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","volume":"62","author":"N Sommer","year":"1997","unstructured":"Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J (1997) Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62(2):156\u2013162. https:\/\/doi.org\/10.1136\/jnnp.62.2.156","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4952_CR72","unstructured":"Speech Pathology Australia (2012) Dysphagia clinical guideline. Melbourne: The Speech Pathology Association of Australia Limited. Available from: https:\/\/www.speechpathologyaustralia.org.au. Accessed Dec 2025"},{"key":"4952_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.553626","volume":"11","author":"P Szczudlik","year":"2020","unstructured":"Szczudlik P, Sobieszczuk E, Szyluk B, Lipowska M, Kubiszewska J, Kostera-Pruszczyk A (2020) Determinants of quality of life in myasthenia gravis patients. Front Neurol 11:553626. https:\/\/doi.org\/10.3389\/fneur.2020.553626","journal-title":"Front Neurol"},{"issue":"2","key":"4952_CR74","first-page":"223","volume":"37","author":"L Ten Holt","year":"2022","unstructured":"Ten Holt L, Horemans HL, de Groot IJM et al (2022) The impact of oropharyngeal dysphagia on health-related quality of life in neuromuscular diseases: a systematic review. Dysphagia 37(2):223\u2013239","journal-title":"Dysphagia"},{"issue":"3","key":"4952_CR75","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","volume":"266","author":"R Topakian","year":"2019","unstructured":"Topakian R, Zimprich F, Iglseder S et al (2019) High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol 266(3):699\u2013706","journal-title":"J Neurol"},{"key":"4952_CR76","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1080\/14656566.2022.2122710","volume":"23","author":"F Vanoli","year":"2022","unstructured":"Vanoli F, Mantegazza R (2022) What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis? Expert Opin Pharmacother 23:1471\u20131474. https:\/\/doi.org\/10.1080\/14656566.2022.2122710","journal-title":"Expert Opin Pharmacother"},{"key":"4952_CR77","unstructured":"Virgilio F, Agostini F, Bernetti A et al (2023) Rehabilitation in myasthenia gravis: a systematic review of the literature. Front Neurol 14:1248312. Published 2023 Oct 12. (Focuses on the gap in exercise protocols)"},{"key":"4952_CR78","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R et al (2022) Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. https:\/\/doi.org\/10.1056\/EVIDoa2100066","journal-title":"NEJM Evid"},{"issue":"1","key":"4952_CR79","volume":"15","author":"B Young","year":"2023","unstructured":"Young B, Smith C, Jones R (2023) Telerehabilitation for bulbar dysfunction in neuromuscular disorders: a feasibility and efficacy study. Int J Telerehabil 15(1):10.5195\/ijt.2023.6502","journal-title":"Int J Telerehabil"},{"key":"4952_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1579859","volume":"16","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Yang M, Guo X, Ma T, Wang Z, Luo T, Peng D, Du X, Huang X, Zhang Y (2025) Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis. Front Immunol 16:1579859. https:\/\/doi.org\/10.3389\/fimmu.2025.1579859","journal-title":"Front Immunol"},{"key":"4952_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1479685","volume":"15","author":"H Zhong","year":"2024","unstructured":"Zhong H, Li Z, Li X, Wu Z, Yan C, Luo S, Zhao C (2024) Initiation response, maximized therapeutic efficacy, and post-treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta-analysis. Front Neurol 15:1479685. https:\/\/doi.org\/10.3389\/fneur.2024.1479685","journal-title":"Front Neurol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04952-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04952-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04952-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:38:52Z","timestamp":1776393532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04952-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4952"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04952-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors consent to the publication of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the authors declare that the opinions expressed are of a personal nature and do not in any way commit the responsibility of the administrations to which they belong.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}